Aeterna Laboratories Inc.: process patent for AE941 accepted in the United States.SAINTE-FOY, Quebec--(BUSINESS WIRE)--Aug. 28, 1996--AETERNA LABORATORIES (ME, TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). : AEL AEL Association Electronique Libre AEL Appalachia Educational Laboratory AEL Arabisch Europese Liga AEL Agence de l'Energie AEL Arab European League AEL Accessible Emission Limit AEL Acceptable Exposure Limit AEL Arquivo Edgard Leuenroth ) Aeterna Laboratories Inc. announced today that the process patent for manufacturing AE941 has been officially accepted by the Patent and Trademark Office in the United States. This technological innovation, developed by a group of researchers headed by Dr. Eric Dupont, Ph.D., president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Aeterna Laboratories, now has patent protection in the United States. It also has patents pending in over 82 countries, including Canada, under the Patent Cooperation Treaty The Patent Cooperation Treaty (PCT) is an international patent law treaty, concluded in 1970. It provides a unified procedure for filing patent applications to protect inventions in each of its Contracting States (see Accession section below for current membership . AE941 is an angiogenesis inhibitor with the potential to control diseases such as cancer with solid tumours, psoriasis and arthritis, as well as some dermatological and ophthalmologic conditions (acne and rosacea Rosacea Definition Rosacea is a skin disease typically appearing in people during their 30s and 40s. It is marked by redness (erythema) of the face, flushing of the skin, and the presence of hard pimples (papules) or pus-filled pimples (pustules), and ). To date, no side effects or toxicity have been associated with its use. The investigational new drug application will be submitted this fall, with the objective of beginning Phase I and II clinical studies on AE941 for use in cancer treatment before the end of 1996. Aeterna Laboratories Inc. is the second largest medical biotechnology company in Quebec and among the 10 largest in Canada. It is involved primarily in the development of angiogenesis inhibitors, which prevent the formation of new blood vessels. CONTACT: Aeterna Laboratories Inc. Richard Bordeleau, 418/527-8525 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion